BVT Knock-Out GNMSF/ DE000VA80VR3 /
24/09/2024 10:23:17 | Chg.+0.100 | Bid10:42:27 | Ask10:42:27 | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
7.960EUR | +1.27% | - Bid Size: - |
- Ask Size: - |
Genmab A/S | 1,030.41 - | 31/12/2078 | Call |
GlobeNewswire
19/08
TEPKINLY® (epcoritamab) Receives Second European Commission Approval for the Treatment of Adults wit...
GlobeNewswire
28/06
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Re...
GlobeNewswire
30/04
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire
03/04
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GlobeNewswire
17/10/2023
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023
GlobeNewswire
25/09/2023
Genmab Announces European Commission Approval of TEPKINLY® (epcoritamab) for Adults with Relapsed or...
GlobeNewswire
04/09/2023
Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improve...
GlobeNewswire
19/10/2021
Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021